Table 2.
Vaccine effectiveness (VE) against (a) incident zoster and (b) post-herpetic neuralgia (PHN).
| Vaccination status | Cases (n) | Person-yearsa | Rate/1000py | Adjusted IRRb (95% CI) | VE (95% CI) |
|---|---|---|---|---|---|
| (a) Outcome: incident zoster | |||||
| Unvaccinated | 8006 | 909,474 | 8.80 | 1.00 | 1.00 |
| Vaccinated | 435 | 137,968 | 3.15 | 0.38 (0.34, 0.42) | 62% (58%, 66%) |
| (b) Outcome: PHN | |||||
| Unvaccinated | 371 | 526,055 | 0.70 | 1.00 | |
| Vaccinated | 8 | 52,861 | 0.15 | 0.19 (0.09, 0.39) | 81% (61%, 91%) |
a
Excludes person-time in the 42 days after vaccination.
b
Incidence rate ratio, adjusted for age in years, month and year of study.